Predicting medication-free treatment response in acute psychosis: Cross-validation from the Finnish need-adapted project

Journal of Nervous and Mental Disease

Volumn 194, Issue 10, 2006, Pages 732-739

  Bola, John Robert ^a   Lehtinen, Klaus ^b   Aaltonen, Jukka ^c   Räkköläinen, Viljo ^d   Syvälahti, Erkka ^d   Lehtinen, Ville ^e  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF JYVÄSKYLÄ   (Finland)

^d UNIVERSITY OF TURKU   (Finland)

^e NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

First episode; Medication free; Psychosis; Schizophrenia; Schizophreniform

Indexed keywords

NEUROLEPTIC AGENT;

ACUTE PSYCHOSIS; ADOLESCENT; ADULT; ARTICLE; CONCEPTUAL FRAMEWORK; DELUSIONAL DISORDER; DISEASE DURATION; FAMILY THERAPY; FEMALE; FINLAND; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PSYCHOSOCIAL CARE; QUASI EXPERIMENTAL STUDY; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; STATISTICAL ANALYSIS; TREATMENT RESPONSE;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FAMILY THERAPY; FEMALE; FINLAND; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MODELS, THEORETICAL; PROGNOSIS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 33750076672     PISSN: 00223018     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.nmd.0000243080.90255.88     Document Type: Article

References (66)

1. Alanen YO (1997) Schizophrenia: Its Origins and Need-Adapted Treatment (p 312). London: Karnac Books.
2. Alanen YO, Lehtinen V, Lehtinen K, Aaltonen J, Rakkolainen V (2000) The Finnish model for early treatment of schizophrenia and related psychoses. In B Martindale, A Bateman, M Crowe, et al. (Eds), Psychosis: Psychological Approaches and Their Effectiveness. London: Gaskell.
3. Alanen YO, Ugelstad E, Armelius BA, Lehtinen K, Rosenbaum B, Sjostrom R (1994) Early treatment for schizophrenic patients: Scandinavian psychotherapeutic approaches (p 162). Oslo, Norway: Scandinavian University Press.
4. APA (1983) The Diagnostic and Statistical Manual of Mental Disorders (3rd ed). Washington (DC): American Psychiatric Association.
5. APA (1994) The Diagnostic and Statistical Manual of Mental Disorders: DSM-IV (3rd ed). Washington (DC): American Psychiatric Association.
6. APA (2004a) Practice guidelines for the treatment of patients with schizophrenia (2nd ed). Suppl Am J Psychiatry. 161:1-56.
7. APA (2004b) Practice Guidelines for the Treatment of Patients With Schizophrenia (2nd ed). Washington (DC): American Psychiatric Association.
8. Bleuler ME (1978) The long-term course of schizophrenic psychosis. In LC Wynne, RL Cromwell, S Matthysse (Eds), The Nature of Schizophrenia: New Approaches to Research and Treatment (pp. 631-636). New York: John Wiley and Sons.
9. Bola JR, Mosher LR (2002) Predicting drug-free treatment response in acute psychosis from the Soteria project. Schizophr Bull. 28:559-575.
10. Bola JR, Mosher LR (2003) The treatment of acute psychosis without neuroleptics: Two-year outcomes from the Soteria project. J Nerv Ment Dis. 191:219-229.
11. Bola JR, Mosher LR, Cohen D (2005) Treatment of newly diagnosed psychosis without anti-psychotic drugs: The Soteria project. In SA Kirk (Ed), Mental Health in the Social Environment: Critical Perspectives (pp. 368-384). New York: Columbia University Press.
12. Buchanan RW, Carpenter WT (1996) Targeted maintenance treatment in schizophrenia: Issues and recommendations. CNS Drugs. 5:240-245.
13. Buckley P (1982) Identifying schizophrenic patients who should not receive medication. Schizophr Bull. 8:429-432.
14. Carpenter WT (1997) The risk of medication-free research. Schizophr Bull. 23:11-18.
15. Carpenter WT, Heinrichs DW (1981) Treatment-relevant subtypes of schizophrenia. J Nerv Ment Dis. 169:113-119.
16. Carpenter WT, McGlashan TH, Strauss JS (1977) The treatment of acute schizophrenia without drugs: An investigation of some current assumptions. Am J Psychiatry. 134:14-20.
17. Carpenter WT, Schooler NR, Goldman H (1988) Treatment, services and environmental factors panel: A national plan for schizophrenia research: Report of the national advisory mental health council. National Institute of Mental Health. Schizophr Bull. 14:82-92.
18. Carpenter WT, Stephens JH (1982) Prognosis as the critical variable in classification of the functional psychoses. J Nerv Ment Dis. 170:688-691.
19. Ciompi L (1980) The natural history of schizophrenia in the long term. Br J Psychiatry. 136:413-420.
20. Cole JO, Klerman GL, Goldberg SC, Group NIoMHPSCCS (1964) Phenothiazine treatment in acute schizophrenia. Arch Gen Psychiatry. 10:246-261.
21. Davis JM, Barter JT, Kane JM (1989) Antipsychotic drugs. In HI Kaplan, BJ Sadock (Eds), Comprehensive Textbook of Psychiatry (pp 1591-1626). Baltimore: Williams and Wilkins.
22. Davis JM, Schaffer CB, Killian GA, Kinard C, Chen C (1980) Important issues in the drug treatment of schizophrenia. Schizophr Bull. 6:70-87.
23. Dixon LB, Lehman AF, Levine J (1995) Conventional antipsychotic medications for schizophrenia. Schizophr Bull. 21:567-577.
24. Eitinger L, Laane C, Langfeldt G (1958) Prognostic value of clinical picture and therapeutic value of physical treatment in schizophrenia and schizophreniform states. Acta Psychiatr Neurol. 33:33-53.
25. Evans JR, Rodnick EH, Goldstein MJ, Judd LL (1972) Premorbid adjustment, phenothiazine treatment and remission in acute schizophrenics. Arch Gen Psychiatry. 27:486-490.
26. Freedman R (2005) The choice of antipsychotic drugs for schizophrenia. N Engl J Med. 353:1286-1288.
27. Gaebel W, Weinmann S, Sartorius N, Rutz W, McIntyre JS (2005) Schizophrenia practice guidelines: International survey and comparison. Br J Psychiatry. 187:248-255.
28. Goldberg SC, Klerman GL, Cole JO (1965) Changes in schizophrenic psychopathology and ward behaviour as a function of phenothiazine treatment. Br J Psychiatry. 111:120-133.
29. Goldstein MJ (1970) Premorbid adjustment, paranoid status and patterns of response to phenothiazine in acute schizophrenia. Schizophr Bull. 1:24-37.
30. Gorenstein EE (1992) The Science of Mental Illness. San Diego: Academic Press.
31. Guze SB (1977) The future of psychiatry: Medicine or social science? J Nerv Ment Dis. 165:225-230.
32. Hempel CG (1965) Aspects of Scientific Explanation. New York: Free Press.
33. Huber G, Gross G, Schuttler R, Linz M (1980) Longitudinal studies of schizophrenic patients. Schizophr Bull. 6:592-605.
34. Jacobsson L, von Knorring L, Mattsson B, Perris C, Edenius B, Kettner B, Magnusson K-E, Villemoes P (1978) The Comprehensive Psychopathology Rating Scale - CPRS - in patients with schizophrenia syndromes. Acta Psychiatr Scand. (suppl 271):39-44.
35. Judd LL, Goldstein MJ, Rodnick EH, Jackson NLP (1973) Phenothiazine effects in good premorbid schizophrenics divided into paranoid-nonparanoid status. Arch Gen Psychiatry. 29:207-211.
36. Kane JM, Marder SR (1993) Pharmacologic treatment of schizophrenia. Schizophr Bull. 19:287-302.
37. Kendell RE (1989) Clinical Validity: The Validity of Psychiatric Diagnosis (pp 305-323). LNB Robins (Trans), E James (Ed). New York: Raven Press Ltd.
38. Langfeldt G (1969) Schizophrenia: Diagnosis and prognosis. Behav Sci. 14:173-182.
39. Langfeldt G (1939) The Schizophreniform States: A Katamnestic Study Based on Individual Reexaminations (pp 134). Copenhagen: Einar Munksgaard.
40. Lehtinen K (1993) Need-adapted treatment of schizophrenia: A five-year follow-up study from the Turku project. Acta Psychiatr Scand. 87:96-101.
41. Lehtinen V, Aaltonen J, Koffert T, Rakkolainen V, Syvalahti E (2000) Two-year outcome in first-episode psychosis treated according to an integrated model: Is immediate neuroleptisation always needed? Eur Psychiatry. 15:312-320.
42. Leshner AI, Burke JD (1991) Foreword. In Caring for People With Severe Mental Disorders: A National Plan for Research to Improve Services (pp iii). Washington (DC): NIMH. DHHS Pub. No. (ADM) 91-1762.
43. Liberman RP, Falloon IRH, Wallace CJ (1984) Drug-psychosocial interactions in the treatment of schizophrenia. In M Mirabi (Ed), The Chronically Mentally Ill: Research and Services (pp 175-212). New York: Spectrum Publications.
44. Lieberman JA, Stroup TS, McEVoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 353:1209-1223.
45. Marder SR, van Kammen DP, Docherty JP, Rayner J, Bunney WE (1979) Predicting drug-free improvement in schizophrenic psychosis. Arch Gen Psychiatry. 36:1080-1085.
46. Mason P, Harrison G, Croudace T, Glazebrook C, Medley I (1997) The predictive validity of a diagnosis of schizophrenia: A report from the International Study of Schizophrenia (ISoS) coordinated by the World Health Organization and the Department of Psychiatry, University of Nottingham. Br J Psychiatry. 170:321-327.
47. May PRA (1968) Treatment of Schizophrenia: A Comparative Study of Five Treatment Methods. New York: Science House.
48. McGlashan TH, Levy ST, Carpenter WT (1975) Integration and sealing over: Clinically distinct recovery styles from schizophrenia. Arch Gen Psychiatry. 32:1269-1272.
49. Mechanic D (1989) Toward the year 2000 in U.S. mental health policymaking and administration. In DA Rochefort (Ed), Handbook on Mental Health Policy in the United States (pp 477-503). New York: Greenwood Press.
50. Miller EA, Leslie DL, Rosenheck RA (2005) Incidence of new-onset diabetes mellitus among patients receiving atypical neuroleptics in the treatment of mental illness. J Nerv Ment Dis. 196:387-395.
51. Mosher LR, Meltzer HY (1980) Drugs and psychosocial treatment: Editor's introduction. Schizophr Bull. 6:8-9.
52. Naz B, Bromet EJ, Mojtabai R (2003) Distinguishing between first-admission schizophreniform disorder and schizophrenia. Schizophr Res. 62:51-58.
53. Popp SM, Trezza GR (1998) Side effects of and reactions to psychotropic medications. In PM Kleespies (Ed), Emergencies in Mental Health Practice (pp 279-311). New York: Guilford.
54. Rakkolainen V, Salokangas R, Lehtinen P (1979) Protective constructions in the course of schizophrenia: A follow-up study. In C Muller (Ed), Psychotherapy of Schizophrenia (pp 233-243). Amsterdam: Excerpta Medica.
55. Rappaport M, Hopkins HK, Hall K, Belleza T, Silverman J (1978) Are there schizophenics for whom drugs may be unnecessary or contraindicated? Int Pharmacopsychiatry. 13:100-111.
56. Schooler NR (1996) Advances in maintenance treatment. Psychiatr Ann. 26:519-522.
57. Schooler NR, Goldberg SC, Boothe H, Cole JO (1967) One year after discharge: Community adjustment of schizophrenic patients. Am J Psychiatry. 123:986-995.
58. Schwartz JE, Fennig S, Tanenberg-Karant M, Carlson G, Craig T, Galambos N, Lavelle J, Bromet EJ (2000) Congruence of diagnoses 2 years after a first-admission diagnosis of psychosis. Arch Gen Psychiatry. 57:593-600.
59. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R (2002) Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry. 159:561-566.
60. Strakowski SM (1994) Diagnostic validity of schizophreniform disorder. Am J Psychiatry. 151:815-824.
61. Thornley B, Adams CE, Awad G (2001) Chlorpromazine versus placebo for schizophrenia. Cochr Database Syst Rev. 2.
62. Vaillant GE (1962) The prediction of recovery in schizophrenia. J Nerv Ment Dis. 135:534-543.
63. Vaillant GE (1964) Prospective prediction of schizophrenic remission. Arch Gen Psychiatry. 11:509-518.
64. Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A (2000) Comparative evaluation of conventional and novel antipsychotics with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res. 43:135-145.
65. Warner R (2004) Recovery From Schizophrenia: Psychiatry and Political Economy (3rd ed). New York: Brunner-Routledge.
66. Young MA, Meltzer HY (1980) The relationship of demographic, clinical and outcome variables to neuroleptic treatment requirements. Schizophr Bull. 6:88-101.